“Through these 2 small punctures, we can manipulate the device with the methodology to sample the entire prostate, both anterior apical and the posterior regions, where we find the vast majority of our cancers,” says Matthew A. Allaway, MD.
In this video, Matthew J. Allaway, MD, discusses the The PrecisionPoint Transperineal Access System, a new and efficient methodology for detecting prostate cancers in patients. Allaway is the founder and president of Perinealogic, urologist and managing partner at Urology Associates, Cumberland, Maryland.
Phase 1B trial to evaluate relugolix and enzalutamide in high-risk prostate cancer
July 24th 2024"Going forward after this study, we hope to be able to expand and potentially look at patients undergoing either surgery or radiation therapy, and really try to determine the potential benefit," says Kelly L. Stratton, MD, FACS.